Numinus’s VP of Psychedelic Neurology, Dr. Evan Lewis, chats with Kelly Martin from Goop to discuss microdosing’s current research findings and the potential for it to be a treatment in neurological disorders.
Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable VANCOUVER (June 24, 2021) – Numinus Wellness…
Educators, researchers see value in studying psilocybin’s effect treating mental health and addiction. Research utilizing magic mushroom derivatives has potential…
The Daily Hive’s Peter Smith speaks to Numinus CEO, Payton Nyquvest, about the business side of psychedelic-assisted therapy research and…
Numinus CEO, Payton Nyquvest, and Chief Operating Officer, Michael Tan, spoke to Mugglehead about an amendment to the company’s Health…
Numinus Chief Operating Officer Michael Tan explains what the company’s recent Health Canada licence amendment, which will allow them to…